Clinical Observation Of Peginterferon (α-2a) Combined With Smokeless Moxibustion In Treating Chronic Hepatitis B

Objective:To observe the clinical curative effect and its safety in the therapy ofpeginterferon(α-2a) combined with smokeless moxibustion in treating chronichepatitis B, and compare with that of in the control group (peginterferonα-2a only).Method:To divide60patients with chronic hepatitis B into the following two groupsrandomly: The control group (peginterferon α-2a only),30cases; The treatment group(peginterferon α-2a combined with smokeless moxibustion),30cases, too. All thepatients were detected respectively in ALT(Liver function)、 The qualitative ofHBeAg、 The responses to HBV-DNA and WBC(neutrophil number in peripheralblood) in the blood routine before the treatment and after12weeks、24weeks and48weeks of the treatment.Then the results are analysed statistical and compared.result:1. The comparison ofALT in the two groups before and after the treatment:⑴Before the treatment, ALT of the patients in the control group and the treatmentgroup were abnormal, there was no significant difference between the two groups（P>0.05）；⑵ALT of the patients in the two groups declined significantly （P<0.05）whentreating at weeks12;⑶ALT of the patients in the treatment group was normal when treating at weeks24,there was a significant difference between the two groups（P<0.05）； ⑷ALT of the patients in the two groups was normal when treating at weeks48,there was no significant difference between the two groups（P>0.05）.2. The comparison of the responses to HBV-DNA in the two groups before and afterthe treatment:⑴Before the treatment, the quantify of HBV-DNA was positive in the two groups,there was no significant difference between the two groups（P>0.05）;⑵When treating at weeks12, there was no HBV-DNA negativity in the two groups,it was not significantly different from the two groups on the rate of HBV-DNAnegativity（P>0.05）;⑶When treating at weeks24,there was no significant difference between the twogroups on the negative conversion rates（P>0.05）;⑷When treating at weeks48,there was no significant difference between the twogroups on the negative conversion rates（P>0.05）；while the reduction greaterthan103IU/mL in HBV-DNA titer in the treatment group was93.33%(28/30),which was significantly higher than that of in the controlgroup(70.00%,21/30)(P<0.05).3. The comparison of negative conversion rate of HBeAg in the two groups beforeand after the treatment:⑴HBeAg in the two groups is positive before the treatment;⑵HBeAg in the two groups is positive when treating at weeks12;⑶HBeAg in some of the treatment group became negative when treating at weeks24,there was a significant difference between the two groups（P<0.05）;⑷The negative conversion rate of HBeAg was46.67%(the treatment group)、23.33%(the control group), there was a significant difference between the twogroups（P<0.05）.4. adverse reaction:4.1The comparison of neutrophil number in peripheral blood in the two groups beforeand after the treatment:⑴The neutrophil number in peripheral blood is normal in the two groups before the treatment, there was no significant difference between the two groups （P>0.05）;⑵The neutrophil number in peripheral blood falled obviously in the two groupswhen treating at weeks12（P<0.05）;⑶The neutrophil number in peripheral blood rised in the treatment group, therewas a significant difference between the two groups（P<0.05）when treating atweeks24；⑷Compared with treating at weeks24,there was no significant difference in thetwo groups in the neutrophil number in peripheral blood when treating at weeks48（P>0.05）; there was a significant difference between the two groups at weeks48（P<0.05）.4.2Apart from myelosuppression, there was no serious adverse reaction in the twogroups: fever(18cases in the treatment group,19cases in the control group),insomnia(2cases in the control group). There was no significant difference in therate of adverse reaction between the two groups（P>0.05）;conclusion：The Chinese combined western medicine therapy “peginterferon combined withsmokeless moxibustion” can promote recovery of liver function faster to in treatingchronic hepatitis B、perfect the biochemical response to HBV-DNA、increase the rateof HBeAg negative conversion、 enhance the tolerance to myelosuppression (theadverse reaction of peginterferon α-2a), the curative effect is superior topeginterferon(α-2a) simple for HBV infection.